Exclusive Summary

• - Guideline-defined first-line heparin antidote listed on the WHO EML, covering high-frequency use in cardiac surgery, interventional cardiology, and dialysis.
• - API meets JP/Ph.Int/KP/EP/USP/BP standards, enabling multi-region registration and rapid distribution partnerships.
• - Offered strengths 5 ml:50 mg and 10 ml:100 mg align with common dosing for intraoperative reversal and dialysis circuit management.
• - Mature generic market with steady demand and occasional supply tightness—reliable supply and compliance are key differentiators.
• - Compared with originator/branded products, established generics deliver clear cost advantages in tenders and hospital purchasing.